Kornimate/medical-research-clean huggingface dataset:
graft patency outcomes in patients undergoing coronary artery bypass grafting via minimally invasive coronary surgery

Conditions: Arteriosclerosis of Coronary Artery Bypass Graft

Summary: this clinical study has been developed to evaluate the clinical outcomes in patients undergoing coronary artery bypass grafting via minimally invasive coronary surgery (mics); a minimally invasive coronary bypass procedure that is done on a beating heart via a smaller chest incision, thus avoiding the invasiveness of the standard procedure.


Eligibility criteria:
inclusion criteria: * \> or equal to 18 and \< or equal to 80 years of age * suitable minimally invasive coronary surgery (mics) candidate for non-emergent first time, single or multivessel coronary artery bypass grafting (on pump or off pump) * left ventricle ejection fraction \>30% * willing and able to provide written informed consent and comply with study requirements exclusion criteria: * severe cerebrovascular disease within 90 days of surgery including history of prior stroke. * previous cardiac surgery procedures such as cabg revisions, surgical ablations or valve replacements * congestive heart failure with a new york heart association (nyha) class iv * history of renal insufficiency (i.e. prior serum creatinine of \>2mg/dl) and/or requiring dialysis * uncontrolled diabetes (i.e. \>2 serum glucose concentrations of \>350 mg/dl) * severe uncontrolled systemic hypertension (i.e. systolic pressure \>160 mmhg) * peripheral/systemic active infection excluding the patient from cardiac surgery * life expectancy of less than 1 year due to other illness such as cancer or pulmonary, hepatic or renal disease * participation in another investigational protocol that may confound the results of this study * female of child bearing potential and lactating or intends to become pregnant during the study * severe distal disease and small posterior lateral targets

Keywords: minimally invasive coronary surgery coronary artery bypass grafting mics cabg
a study of toripalimab+ pemetrexed plus carboplatin in patients with egfr-mutation positive and t790m negative after progression on egfr-tki treatment

Conditions: NSCLC

Summary: js001 combined with pemetrexed plus carboplatin for treatment of recurrent or advanced non-small-cell lung cancer with egfr-mutation positive and t790m negative after progression on egfr-tki treatment：a multi-center, single arm phase ii study


Eligibility criteria:
inclusion criteria: only the patients meeting all the following criteria can be eligible to participate in the trial: * histologically and/or cytologically confirmed advanced or recurrent non-small cell lung cancer with egfr sensitive mutation (exon 19 deletion, exon 21 l858r), and meeting the following conditions at the same time: * previous first-line egfr-tki monotherapy with clinical benefit, followed by progression of disease; * no exon 20 t790m mutation after failure of egfr-tki therapy; * at least one measurable lesion (in accordance with recist 1.1); exclusion criteria: patients who fulfill any of the following criteria must be excluded from the study: * histologically or cytopathologically confirmed combined with small cell lung cancer component or squamous cell carcinoma component \>10%; * combined with other driver gene mutation with known drug therapy, including but not limited to alk rearrangement, ros1 mutation, braf600e mutation etc.; * previous systemic chemotherapy for advanced nsclc; * egfr-tki therapy within two weeks prior to enrollment;
the water intake trial: pilot phase

Conditions: Chronic Kidney Disease

Summary: the investigators are conducting a six-week randomized controlled pilot trial to assess the feasibility and safety of increased water intake in patients with chronic kidney disease.the investigators will study 30 patients (age 30 to 80 with an estimated glomerular filtration rate between 30 and 60 ml/min/1.73m2 and microalbuminuria \[albumin to creatinine ratio \>2.8 mg/mmol (if female) or \>2.0 mg/mmol if male)\].the investigators will randomize patients (in a 2:1 ratio) to a fluid-intervention group or control group. participants who are randomized to the hydration-intervention group will be asked to consume 1.0 to 1.5 l water per day (depending on sex and weight) in addition to usual consumed beverages, for 6 weeks. participants in the control group will be advised to consume their usual amount of fluid. the investigators hypothesize that patients will be able to increase and maintain a higher fluid intake with stable blood chemistry, particularly serum sodium.


Eligibility criteria:
inclusion criteria: * age 30-80 years * able to provide informed consent and willing to complete follow-up visits. * estimated glomerular filtration rate between 30 and 60 ml/min/1.73m2 * microalbuminuria \[albumin to creatinine ratio \>2.8 mg/mmol (if female) or \>2.0 mg/mmol if male)\] exclusion criteria: * self-reported fluid intake \>10 cups/day or 24-hr urine volume \>3l. * enrolled in another randomized controlled trial that could influence the intervention, outcomes or data collection of this trial (or previously enrolled in this trial) * received one or more dialysis treatments in the past month * kidney transplant recipient (or on waiting list) * pregnant or breastfeeding * history of kidney stones in past 5 years * less than two years life expectancy * serum sodium \<130 meq/l without suitable explanation * serum calcium \>2.6 mmol/l without suitable explanation * currently taking hydrochlorothiazide \>25 mg/d, indapamide \>1.25 mg/d, furosemide \>40 mg, or metolazone \>2.5 mg/d * currently taking lithium * patient is under fluid restriction (\< 1.5 l a day or more) for kidney disease, heart failure, or liver disease, and meets any of the following criteria: i) end stage of the disease (heart left ventricular ejection fraction \<40%, nyha class 3 or 4, or end stage cirrhosis) or ii) hospitalization secondary to heart failure, ascites and/or anasarca
a study to evaluate the efficacy of an acellular dermal template for the treatment of full thickness skin defects

Conditions: Full Thickness Skin Defects

Summary: in this study the efficacy of an acellular dermal template (novomaix), combined with split thickness skin grafts, for use in patients with full thickness skin defects, is tested. results will be compared intra-patient with those obtained after conventional treatment with split thickness skin grafts. the investigators expect this treatment to provide better outcome regarding scar quality.

using dermal substitutes in combination with a split-thickness skin graft (stsg) is a well acknowledged therapy in burns and reconstructive surgery. nevertheless, the ideal substitute is not available yet. we therefore want to investigate the use of an acellular dermal template (novomaix), in combination with stsg, to treat these defects. patients with with full thickness skin defects will be included in this study. this phase ii study aims to investigate the efficacy of the use of this dermal matrix, with regard to scar quality as determined for elasticity at 3 months after treatment. moreover, graft take (5-7 days after treatment), epithelialisation (5-7 days and 2-3 weeks), and scar quality (3 and 12 months after treatment, as determined for elasticity, colour/pigmentation, and using a subjective scar assessment scale) will be evaluated.

Eligibility criteria:
inclusion criteria: * age ≥18 years (for zurich: ≤ 18 years) * full thickness skin defects configured in such a way that two comparable and measurable areas can be grafted, both of minimally 3x3 cm * ≤ 50% tbsa full thickness skin defects at time of intervention * informed consent by the patient and/or legal representatives. exclusion criteria: * patients with infected wounds * full thickness skin wounds located in face and/or genitals will not be included * pregnant or breast feeding females * patients with known concomitant medical conditions that may interfere with normal wound healing (e.g. immune deficiency, hiv, uncontrolled diabetes, treatment with corticoid therapy, collagenoses, cancer) * known allergy against porcine collagen or elastin * patients that are expected (according to the responsible medical doctor) to be non-compliant to the study protocol. (this includes patients with severe cognitive dysfunction/impairment and severe psychiatric disorders) * previous enrolment of the patient into the current study

Keywords: burns dermal substitute scar quality reconstruction wound healing wound closure
thin database study: resource use and outcomes in patients with adrenal insufficiency prescribed hydrocortisone: immediate, or modified release, or prednisolone

Conditions: Adrenal Insufficiency

Summary: to describe clinical outcomes and both primary and secondary care health care resource use in patients who have been prescribed either immediate-release (ir) hydrocortisone or modified-release (mr) hydrocortisone or prednisolone in the uk.


Eligibility criteria:
inclusion criteria: 1. cohort 1 (ir hydrocortisone): all patients with a read code for ai and a prescription of ir hydrocortisone between 2010 and data extraction but no prescription for mr hydrocortisone at any time during this period, and no earlier prescription for ir prednisolone during this period 2. cohort 2 (ir prednisolone): all patients with a read code for ai and a prescription of ir prednisolone between 2010 and data extraction but no prescription for mr prednisolone at any time during this period, and no earlier prescription for ir prednisolone during this period 3. cohort 3a (mr hydrocortisone): all patients with a read code for ai and a prescription of mr hydrocortisone between 2010 and data extraction 4. cohort 3b (ir to mr hydrocortisone): a sub-set of patients from cohort 3a, who have switched from ir to mr hydrocortisone. 5. a list of pre-defined read codes will be used to identify all patients with primary or secondary ai or cah in the thin database. exclusion criteria: 1)patients who have not received a prescription of hydrocortisone or prednisolone in the past five years will be excluded as the aim of the study is to describe recent experience.
compassionate use of beclomethasone in treating patients with graft-versus-host disease of the gastrointestinal tract

Conditions: Graft Versus Host Disease

Summary: rationale: beclomethasone may be effective in treating patients who have graft-versus-host disease of the gastrointestinal tract. purpose: compassionate use of beclomethasone in treating patients who have graft-versus-host disease of the gastrointestinal tract that has not responded to previous therapy.

objectives: * provide beclomethasone dipropionate to patients with gastrointestinal graft-versus-host disease refractory to standard therapy or with a contraindication to systemic steroids. * minimize the serious side effects associated with systemic steroid use in these patients. outline: patients receive oral beclomethasone dipropionate 4 times daily for 28 days in the absence of graft-versus-host disease progression or unacceptable toxicity. patients may then receive a second course for 31 days if symptoms of graft-versus-host disease persist. patients may receive up to 4 treatments (1 or 2 courses each) per year. projected accrual: a total of 24-45 patients will be accrued for this study within 3 years.

Eligibility criteria:
disease characteristics: * clinically or pathologically confirmed graft-versus-host disease of the gastrointestinal tract * failed standard therapy with or has a contraindication to systemic immunosuppressive agents * no clinically significant intestinal infection (confirmed by stool culture) * no persistent vomiting of all oral intake * not a candidate for approved beclomethasone dipropionate enteron pharmaceuticals protocol patient characteristics: age * 4 to 70 performance status * not specified life expectancy * not specified hematopoietic * not specified hepatic * not specified renal * not specified other * able to swallow medication prior concurrent therapy: biologic therapy * not specified chemotherapy * not specified endocrine therapy * see disease characteristics radiotherapy * not specified surgery * not specified

Keywords: graft versus host disease
preconditioning with limb ischemia for subarachnoid hemorrhage

Conditions: Ischemic Preconditioning

Summary: the purpose of this study is to learn about protecting the brain from dangerous low blood flow.


Eligibility criteria:
inclusion criteria: * patients with aneurysmal subarachnoid hemorrhage whose initial angiogram show an aneurysm and patients with clipped aneurysm will be eligible for enrollment. * patients will be enrolled within 96 hours of bleeding onset, if informed consent is obtained from the participant or health care proxy, as appropriate. exclusion criteria: * hunt hess scale \> 4 * inability to undergo limb preconditioning due to local wound or tissue breakdown, history of peripheral extremity vascular disease or patient discomfort. * inability to obtain informed consent from the patient or a health care proxy. * ankle-brachial index \< 0.7 * inability to start limb preconditioning within 4 days of bleeding. * inability to precondition a leg that is not-plegic (that is preserved anti- gravity strength) and has not been accessed for catheter angiography * age\<18 years * pregnant women * prisoners
a longitudinal observational study of patients undergoing therapy for imisc

Conditions: Atopic Dermatitis; Alopecia Areata; Hidradenitis Suppurativa; Vitiligo; Psoriasis; Chronic Spontaneous Urticaria

Summary: target-derm is a longitudinal, observational study of adult and pediatric patients being managed for atopic dermatitis and other immune-mediated inflammatory skin conditions (imisc) in usual clinical practice. target-derm will create a research registry of patients with imisc within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

target-derm is a longitudinal, observational study of adult and pediatric patients being managed for atopic dermatitis and other immune-mediated inflammatory skin conditions (imisc) in usual clinical practice. target-derm will create a research registry of patients with imisc within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies. the duration of follow-up for participants enrolled in the eu is limited to 5-years. those within in us and canada may consent to indefinite follow-up.

Eligibility criteria:
inclusion criteria: * 1. adults and children (all ages) with atopic dermatitis or other immune-mediated inflammatory skin conditions been prescribed any dermatologic treatment. * 2. participant has plans for future visits at the site for continued management of imisc. exclusion criteria: * 1. inability to provide written informed consent/assent. * 2. subjects participating in any interventional study or trial for imisc treatment trial at the time of enrollment. patients may be enrolled in target-derm once participation in the trial is complete. note: participants may be enrolled in other registries or studies where imisc treatment outcomes are observed and/or reported (such as center-based registries).

Keywords: atopic dermatitis imisc registry observational immune-mediated inflammatory skin conditions
prophylactic effect of memantine in chronic tension-type headache

Conditions: Tension-Type Headache

Summary: the purpose of this study is to test whether memantine has a prophylactic effect on chronic tension-type headaches.


Eligibility criteria:
inclusion criteria: * chronic tension-type headache * normal urine ph exclusion criteria: * more than 1 migraine attack/month * other major illnesses * overuse of medicine/alcohol * women not using ac * pregnant/breast-feeding women * allergy to memantine

Keywords: chronic tension-type headache
distribution of topical nasal medication within the nasal cavity and sinuses by radiographic comparison

Conditions: Chronic Sinusitis

Summary: the purpose of this study is to determine the distribution of nasal sprays and nasal drops when used.

the purpose of this study is to determine the distribution of nasal sprays and nasal drops when used. the study hypothesizes that nasal drops will reach the frontonasal region more often than nasal sprays.

Eligibility criteria:
inclusion criteria: * adult able to perform activities of daily living exclusion criteria: * signs or symptoms of acute or chronic paranasal sinus disease * history of sinus surgery * symptomatic deviated septum * active seasonal allergies * allergies to contrast * history of nasal polyposis * pregnant or breast feeding women * neck or back problems that would prevent a subject from kneeling on the floor and crouching over * currently taking metformin or amiodarone * students or stff under the direct supervision of the investigators * cognitive impairment * terminal illness

Keywords: nasal spray nasal drop intranasal medication
evaluation of a minimally invasive image-guided surgery system for hepatic ablation procedures

Conditions: Liver Cancer

Summary: this study was designed in two phases: phase i is designed to confirm that the surgeon is able to perform accurate liver surface registration including standard liver features used as landmarks during a scheduled laparoscopic liver ablation procedure and acquires a level of comfort with the procedure. the surface of the liver will be manually swabbed with the study tracked laparoscopic probe with landmarks noted during data collection. after registration of the liver is obtained, the registration points obtained during this procedure will be evaluated by the surgeon by moving the tracked laparoscopic probe over the liver surface and evaluating the location of the tracked laparoscopic probe displayed on the guidance system three dimensional (3d) image. the surgeon will accept or reject the registration accuracy. the hypothesis is that the surgeon will be able to successfully acquire liver surface registrations with a small learning curve for technique and will be able to proceed to phase ii of the study. phase ii contains the registration process included above but adds the additional process of tracking the ablation probe used to perform tumor ablation by attaching the pathfinder multi-tool adaptor and collecting data showing the location of the ablation probe as tracked and displayed on the pathfinder three dimensional (3d) image. the surgeon will use ultrasound (us) guidance to locate tumor location during the laparoscopic procedure. the images collected during this process will be recorded by pathfinder.

the pathfinder system used during this study is used for data collection purposes only and is not used during the surgical procedure as an image guided system. preoperative computed tomography (ct) scans, obtained as standard of care, will be used to generate the image guided liver system 3d liver surface images used during the study. during the laparoscopic procedure, the pathfinder device will be inserted through the standard laparoscopic ports (5mm or 10mm) being used for the staging procedure. a total study population will include 30 subjects: 10 in phase i and 20 in phase ii that complete the laparoscopic procedure scheduled.

Eligibility criteria:
inclusion criteria: * scheduled for laparoscopic liver ablation procedure * had a preoperative ct image that includes the liver exclusion criteria: * severe cirrhosis of the liver * kidney failure or dialysis * unable to consent

Keywords: liver cancer tumor ablation pathfinder
prophylaxis versus on demand treatment for children with hemophilia a

Conditions: Hemophilia A

Summary: comparison of the effect of three times a week prophylaxis on all bleeds with on-demand treatment for children with severe hemophilia a.


Eligibility criteria:
inclusion criteria: * male, aged 2-16yrs * severe hemophilia a (\<1% fviii:c \[blood clotting factor viii:c\] ) * minimum of at least 50 documented ed (exposure day) prior to enrolment * no measurable inhibitor activity at baseline and history of fviii inhibitor antibody formation * parents or legal guardians document, sign, and date informed consent exclusion criteria: * another bleeding disease that is different from hemophilia a * known hypersensitivity to the active substance, mouse or hamster protein * thrombocytopenia (platelet count \<100 000/mm3) based on previous medical records
phase i/ii study of neoadjuvant chemoradiotherapy with s-1/ oxaliplatin in patients with gastric cancer: randomized phase ii study of s-1/rt vs. s-1/oxaliplatin/rt

Conditions: Phase I: To Determine the Maximum Tolerated Dose (MTD); Phase II: To Assess the Pathologic CR Rate and Feasibility Following Neoadjuvant Chemoradiation Therapy With S1/Oxaliplatin

Summary: to evaluate the efficacy of preoperative s-1/oxaliplatin/rt in locally advanced gastric cancer


Eligibility criteria:
inclusion criteria: * patients older than 18 years * patients with localized, histologically confirmed gastric or gastroesophageal adenocarcinoma ③ localized gastric cancer of clinical stage (t2n(+), t3/t4) * ecog performance status of 0 to 1 ⑤ adequate organ function as evidenced by the following; absolute neutrophil count \> 1.5 x 109/l; platelets \> 100 x 109/l; total bilirubin ≤1.5 unl; ast and/or alt \< 5 unl; creatinine clearance ≥ 50ml/min ⑥ written informed consent form exclusion criteria: * t1 (regardless of n stage), t2n0 * m1 ③ peritoneal seeding ④ uncontrolled medical condition
octabaix intervention study

Conditions: Falls; Malnutrition

Summary: objective: to determine the effectiveness of an individual multifactorial intervention on falls and undernutrition risk in very older people in the community.

design: randomized, controlled trial. method: three hundred and twenty eight people born in 1924, after recruitment will be followed for a three year period. subjects received two in-home visits from a trained nurse or physicians who assessed falls and nutritional risk factors using an algorithm. the intervention consisted of recommendations to the subject and their primary physician, and other providers, telephone calls, and exercise and nutritional plan. control subjects received a general primary care assessment. measurements: the primary outcome were rate of falls and rate of undernourished risk. secondary outcomes included different geriatrics characteristics.the outcomes of this study will provide important new information to reduce the incidence of falls and the risk of undernutrition of this population by intervention. significant differences are not expected according to social-demographics sex and other factors, but they are expected by other obtained factors and indices that could allow to detection of octogenarian people with great risk of deterioration in just a short time.

Eligibility criteria:
inclusion criteria: * subjects born in 1924 of one of the 7 participating health centers and noninstitutionalized exclusion criteria: * institutionalized

Keywords: elderly nutrition